TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed prostate cancer pathologically proven by prostate biopsy~2. Prostate biopsy histology grade ≥ Gleason 3+3=6.~3. Patients considered as candidates for and medically fit to undergo prostatectomy~4. At least 10 days after most recent prostate biopsy~5. No known problems with peripheral IV or central line access~6. Able to tolerate urinary straight catheter placement~7. Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits.~8. Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures.~Exclusion Criteria:~1. Prior pelvic external beam radiation therapy or brachytherapy~2. Chemotherapy for prostate cancer~3. Hormone deprivation therapy~4. Investigational therapy for prostate cancer~5. Hemorrhagic cystitis or active prostatitis~6. Unable to lie flat during or tolerate PET/CT~7. Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer~8. No prostatectomy scheduled prior to follow-up visit (12 to 72 hours post imaging)~9. Serum creatinine \> 1.5 mg/dL or creatinine clearance \< 50 mL/min/1.73m2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Primary Prostate Cancer (Type: EXPERIMENTAL): Patients will be imaged with 18F-DCFBC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Among other criteria, patients must meet all of the following conditions to be eligible to be in the study:~1. 18 years of age or older.~2. Have a cancer type that is known to express NY-ESO-1, including (but not limited to) cancer of the bladder, breast, ovary, non-small cell lung cancer, myeloma, sarcoma or melanoma.~3. Have cancer that has progressed after any therapies with curative potential or approved salvage therapies (if such therapies exist).~4. Have evaluable or measurable tumors.~5. Have adequate blood, bone marrow, liver and kidney function as determined by laboratory tests.~6. Have a sample of tumor tissue available for NY-ESO-1 testing at a central laboratory.~7. If of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment.~Exclusion Criteria:~Among other criteria, patients who meet any of the following conditions are NOT eligible to be in the study:~1. Are receiving treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (inhaled or topically applied steroids are permitted).~2. Has a known infection with HIV, HBV or HCV, or any other active infection requiring systemic antibiotic treatment.~3. Has active central nervous system tumors.~4. Any underlying medical condition that in the Principal Investigator's opinion will make the administration of study drug hazardous or otherwise interfere with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Histologically confirmed Hodgkin Lymphoma stage I, II unfavorable according to EORTC (European Organisation for Research and Treatment of Cancer) criteria, with exclusion of stage II B bulky.~* Previously untreated~* ECOG (Eastern Cooperative Oncology Group) performance status 0 - 2~* Staging with FDG-PET (fluorodeoxyglucose positron emission tomography)~* Written informed consent~* Adequate liver and renal function (total serum bilirubin \< 2.5 x ULN, AST/SGOT and/or ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement, serum creatinine \< 2.5 x ULN)~Exclusion Criteria:~* Concomitant cardiac, pulmonary, neurologic, psychiatric or metabolic severe disease.~* Uncontrolled diabetes mellitus (with fasting glucose levels above 200mg/dl)~* Other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast or other cancer from which the patient has been disease-free for ≥ 3 years~* Patients with a known history of HIV seropositivity~* Active HCV infection (PCR + ; AST\> 1.5-2x UN)~* Woman who is pregnant or breast feeding. Fertile patients not willing to use effective contraception during the study and 3 months after the end of treatment. Women of childbearing potential (WOCBP) are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months.~* Negative pregnancy test at baseline is required (serum β HCG).~* Male patient whose sexual partner(s) are WOCBP who are not willing to use a effective contraception during the study and 3 months after the end of treatment~* Nodular lymphocyte prevalence histological subtype

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dose dense ABVD (Type: EXPERIMENTAL): 1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* IBD Group:~  * Biopsy confirmed Crohn's Disease~ * Qualifying scores on Multidimensional Fatigue Inventory and Pittsburgh Sleep Quality Index~* Healthy Volunteer Group:~  * Does not meet any exclusion criteria~Exclusion Criteria:~* IBD Group:~  * Meeting criteria for active alcohol or substance abuse or dependence~ * Current ongoing treatment with Wellbutrin~ * Females who are pregnant or plan to become pregnant within three months~ * Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)~ * Current IBD flare requiring hospitalization with intravenous steroid treatment~ * Other acute medical conditions or a history of chronic inflammatory condition other than IBD~ * Hemoglobin \<10 with age and gender adjustments~ * History of seizure disorder~ * Acute infection within seven days~* Healthy Volunteer Group:~  * History or current episode of psychiatric disorder by Diagnositic and Statistical Manual (DSM-IV)~ * Current ongoing treatment with psychoactive medications~ * Medications for sleep in previous two weeks~ * Females who are pregnant or plan to become pregnant within three months~ * History of IBD, epilepsy, rheumatoid arthritis, lupus~ * Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Behavioral Counseling (Type: OTHER): Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
- Behavioral counseling + bupropion-SR (Type: OTHER): Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
- Healthy Control (Type: NO_INTERVENTION): The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Substance Use Prevention Campaign for American Indian Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Attend 7th grade in targeted schools that are on or near American Indian reservation and have received parental consent~Exclusion Criteria:~* No parental consent

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Be Under Your Own Influence Intervention (Type: EXPERIMENTAL): School-based anti-substance use communications campaign
- Control (Type: NO_INTERVENTION): Assessment only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight weeks~* HbA1c greater than or equal to 7.0% and less than 10.0%~* BMI (Body Mass Index) less than 35 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last 12 weeks~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide 0.9 mg + glibenclamide placebo
- Glibenclamide (Type: ACTIVE_COMPARATOR): Glibenclamide 1.25-2.5 mg + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Has SARS-CoV-2-positive antigen or molecular diagnostic test (by validated SARS-CoV-2 antigen, RT-PCR, or other molecular diagnostic assay, using an appropriate sample such as NP, nasal, oropharyngeal \[OP\], or saliva) ≤72 hours prior to randomization and no alternative explanation for current clinical condition. A historical record of positive result from test conducted ≤72 hours prior to randomization is acceptable.~* Has symptoms consistent with COVID-19, as determined by investigator, with onset ≤10 days before randomization~* Hospitalized for ≤72 hours with at least 1 of the following at randomization; patients meeting more than one criterion will be categorized in the most severely affected category:~  1. Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen~ 2. Cohort 1: Maintains O2 saturation \>93% on low-flow oxygen as defined in the protocol~ 3. Cohort 2: High-intensity oxygen therapy without mechanical ventilation as defined in the protocol~ 4. Cohort 3: On mechanical ventilation~Key Exclusion Criteria:~* Phase 1 Only: Patients maintaining O2 saturation \>94% on room air~* In the opinion of the investigator, unlikely to survive for \>48 hours from screening~* Receiving extracorporeal membrane oxygenation (ECMO)~* Has new-onset stroke or seizure disorder during hospitalization~* Initiated on renal replacement therapy due to COVID-19~NOTE: Other protocol defined inclusion / exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On Low-Flow Oxygen (Type: EXPERIMENTAL): Cohort 1 (C1): O2 saturation \>93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
- With COVID-19 symptoms but not requiring supplemental O2 (Type: EXPERIMENTAL): Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
- High O2 No Mechanical Ventilation (Type: EXPERIMENTAL): Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
- On Mechanical Ventilation (Type: EXPERIMENTAL): Cohort 3 (C3): On mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing diagnostic or therapeutic ERCP.~Exclusion Criteria:~* Unwillingness or inability to consent for the study;~* Age \< 18 years old;~* Intrauterine pregnancy;~* Breastfeeding mother;~* Standard contraindications to ERCP;~* Allergy to NSAIDs;~* Received NSAIDs in prior 7 days;~* Renal failure (Cr \>1.4mg/dl=120umol/l);~* Active or recurrent (within 4 weeks) gastrointestinal hemorrhage;~* Acute pancreatitis within 72 hours;~* Known pancreatic head mass;~* Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram;~* ERCP for biliary stent removal or exchange without anticipated pancreatogram;~* Known active cardiovascular or cerebrovascular disease.~* Presence of coagulopathy before the procedure or received anticoagulation therapy within three days before the procedure;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Pre-ERCP group (Type: EXPERIMENTAL): Pre-ERCP rectal Indomethacin in all patients.
- Post-ERCP group (Type: ACTIVE_COMPARATOR): Post-ERCP rectal Indomethacin in high-risk patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline and Nicotine Interactions in Humans (VA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male smokers, aged 18 to 55 years~* History of smoking daily for the past 12 months, at least 15 cigarettes daily~* Carbon Monoxide (Alveolar) level \> 10ppm~* For women: not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods~Exclusion Criteria:~* History of heart disease, renal or hepatic diseases~* other medical conditions that the physician investigator deems as contraindicated for the subject to be in the study~* Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)~* recent psychiatric diagnosis and treatment for Axis I disorders including~* major depression, bipolar affective disorder,~* schizophrenia and panic disorder within the past year~* Current dependence on alcohol~* drugs or treatments for drug~* alcohol addiction within the past 5 years~* Allergy to varenicline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo First, varenicline, + IV Nic (Type: EXPERIMENTAL): Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
- Varenicline first, placebo, + IV Nic (Type: EXPERIMENTAL): Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 19 to 45 inclusive~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2~Exclusion Criteria:~* Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds~* History of allergy or intolerance to metformin or other similar acting agents~* Prior exposure to saxagliptin~* Prior exposure to metformin within 3 months of study drug administration.~* Estimated creatinine clearance (Clcr) of \< 80ml/min using the Cockcroft Gault formula

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed) (Type: EXPERIMENTAL): Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M \[fasted\]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M \[fed\]) followed by S/M under fasting conditions (S/M \[fasted\]) followed by S + M under fed conditions (S + M \[fed\])
- S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed) (Type: EXPERIMENTAL): Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
- S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted) (Type: EXPERIMENTAL): Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
- S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted) (Type: EXPERIMENTAL): Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Subjects affected by HD or those who are at risk for HD by virtue of having a first-degree relative with the illness, methamphetamine abuse or dependence, as well as normal controls, can participate.~* All subjects will be above the age of 21.~* Subjects will be recruited from clinical settings, and will also be self-referred.~Exclusion criteria:~* Individuals with pacemakers, infusion pumps, or metallic shrapnel will be excluded from MRI assessments.~* Such implanted metals may be attracted by the MRI machine and put the individual at risk.~* Moreover, individuals with a history of brain surgery and/or skull fracture will also be excluded.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Subjects with mild or moderate Huntington's Disease
- 2 (Type: None): Normal Controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have received at least one dose of dabrafenib or combination with trametinib as part of a compassionate use for the treatment of metastatic melanoma, with deadline the start of treatment the April 30, 2014.~Exclusion Criteria:~* Patients with a history not available.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib (Type: None): None
- Dabrafenib plus Trametinib (Type: None): Patients treated with Dabrafenib plus Trametinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete